<DOC>
	<DOC>NCT00140387</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®). Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of Allogeneic Prostate GVAX® on serum PSA levels will be evaluated and antitumor responses will be quantitated.</brief_summary>
	<brief_title>Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis of adenocarcinoma prostate cancer No evidence of measurable metastatic disease An ECOG performance status of 0 or 1 Previous hormonal therapy of any type for prostate cancer Any previous chemotherapy, or prior investigational therapy for prostate cancer Prior Immunotherapy Prior treatment with gene therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>GVAX</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cells</keyword>
</DOC>